NASDAQ:NEO NeoGenomics (NEO) Stock Price, News & Analysis $7.42 -0.08 (-1.07%) Closing price 04:00 PM EasternExtended Trading$7.42 0.00 (0.00%) As of 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About NeoGenomics Stock (NASDAQ:NEO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get NeoGenomics alerts:Sign Up Key Stats Today's Range$7.28▼$7.5050-Day Range$6.39▼$10.2752-Week Range$6.08▼$19.12Volume1.00 million shsAverage Volume1.15 million shsMarket Capitalization$954.92 millionP/E RatioN/ADividend YieldN/APrice Target$13.83Consensus RatingHold Company OverviewNeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.Read More… NeoGenomics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks77th Percentile Overall ScoreNEO MarketRank™: NeoGenomics scored higher than 77% of companies evaluated by MarketBeat, and ranked 230th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingNeoGenomics has received a consensus rating of Hold. The company's average rating score is 2.45, and is based on 5 buy ratings, 6 hold ratings, and no sell ratings.Amount of Analyst CoverageNeoGenomics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about NeoGenomics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for NeoGenomics are expected to grow in the coming year, from ($0.20) to $0.09 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NeoGenomics is -11.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NeoGenomics is -11.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeoGenomics has a P/B Ratio of 1.06. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about NeoGenomics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.69% of the outstanding shares of NeoGenomics have been sold short.Short Interest Ratio / Days to CoverNeoGenomics has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NeoGenomics has recently decreased by 4.62%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNeoGenomics does not currently pay a dividend.Dividend GrowthNeoGenomics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.69% of the outstanding shares of NeoGenomics have been sold short.Short Interest Ratio / Days to CoverNeoGenomics has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NeoGenomics has recently decreased by 4.62%, indicating that investor sentiment is improving. News and Social Media3.1 / 5News Sentiment0.65 News SentimentNeoGenomics has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.03 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for NeoGenomics this week, compared to 5 articles on an average week.Search Interest11 people have searched for NEO on MarketBeat in the last 30 days. This is an increase of 10% compared to the previous 30 days.MarketBeat Follows4 people have added NeoGenomics to their MarketBeat watchlist in the last 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, NeoGenomics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $512,438.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 2.40% of the stock of NeoGenomics is held by insiders.Percentage Held by Institutions98.50% of the stock of NeoGenomics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about NeoGenomics' insider trading history. Receive NEO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeoGenomics and its competitors with MarketBeat's FREE daily newsletter. Email Address NEO Stock News HeadlinesInsider Buying: NeoGenomics, Inc. (NASDAQ:NEO) COO Acquires 5,700 Shares of StockMay 14, 2025 | insidertrades.comNeoGenomics, Inc. (NASDAQ:NEO) Director Acquires $31,120.00 in StockMay 10, 2025 | insidertrades.comTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... This is what President Trump said: "Our currency is crashing and will soon no longer be the world standard, which will be our greatest defeat, frankly, in 200 years." Why Would He Say This?May 28, 2025 | Augusta Precious Metals (Ad)NeoGenomics, Inc. (NASDAQ:NEO) CEO Buys $148,932.00 in StockMay 9, 2025 | insidertrades.comNeoGenomics, Inc. (NASDAQ:NEO) Director Buys 10,000 SharesMay 8, 2025 | insidertrades.comBrokerages Set NeoGenomics, Inc. (NASDAQ:NEO) PT at $13.83May 27 at 2:39 AM | americanbankingnews.comNeoGenomics introduces c-MET companion diagnostic for NSCLCMay 23, 2025 | finance.yahoo.comNeoGenomics Launches c-MET CDx Assay to Guide Treatment Decisions for Advanced Non-Small Cell Lung CancerMay 22, 2025 | businesswire.comSee More Headlines NEO Stock Analysis - Frequently Asked Questions How have NEO shares performed this year? NeoGenomics' stock was trading at $16.48 at the beginning of the year. Since then, NEO shares have decreased by 55.0% and is now trading at $7.42. View the best growth stocks for 2025 here. How were NeoGenomics' earnings last quarter? NeoGenomics, Inc. (NASDAQ:NEO) issued its quarterly earnings results on Tuesday, April, 29th. The medical research company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by $0.06. The company's revenue was up 7.6% compared to the same quarter last year. Read the conference call transcript. Does NeoGenomics have any subsidiaries? NeoGenomics subsidiaries include these companies: Inivata Limited, Trapelo Health, Genesis Acquisition Holding Corp, Genoptix, Clarient Inc, GE Medical Holding AB., Path Labs LLC, and others. Who are NeoGenomics' major shareholders? Top institutional shareholders of NeoGenomics include Vanguard Group Inc. (11.08%), First Light Asset Management LLC (4.70%), Greenhouse Funds LLLP (3.66%) and Brown Advisory Inc. (3.01%). Insiders that own company stock include Jeffrey Scott Sherman, Warren Stone, Stephen M Kanovsky, Alicia C Olivo, Anthony P Zook, David Brian Perez and Lynn A Tetrault. View institutional ownership trends. How do I buy shares of NeoGenomics? Shares of NEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of NeoGenomics own? Based on aggregate information from My MarketBeat watchlists, some other companies that NeoGenomics investors own include Humana (HUM), American Water Works (AWK), NVIDIA (NVDA), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR) and AUO (AUOTY). Company Calendar Last Earnings4/29/2025Today5/28/2025Next Earnings (Estimated)8/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Testing laboratories Sub-IndustryBusiness Services Current SymbolNASDAQ:NEO CIK1077183 Webwww.neogenomics.com Phone(239) 768-0600Fax239-690-4237Employees2,100Year Founded2002Price Target and Rating Average Stock Price Target$13.83 High Stock Price Target$22.00 Low Stock Price Target$8.50 Potential Upside/Downside+86.4%Consensus RatingHold Rating Score (0-4)2.45 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($0.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$87.97 million Net Margins-11.92% Pretax Margin-12.21% Return on Equity-2.10% Return on Assets-1.17% Debt Debt-to-Equity Ratio0.38 Current Ratio1.98 Quick Ratio1.91 Sales & Book Value Annual Sales$672.36 million Price / Sales1.42 Cash Flow$0.27 per share Price / Cash Flow27.03 Book Value$7.02 per share Price / Book1.06Miscellaneous Outstanding Shares128,695,000Free Float126,791,000Market Cap$954.92 million OptionableOptionable Beta1.60 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:NEO) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredTrump Quietly Planning $15 Trillion Crypto ShockerMost investors are still unaware, but I believe a new White House action may have quietly opened the floodgate...Paradigm Press | SponsoredUrgent: Make this trade before you hit your pillow tonight… Most people waste 8 hours every night… And 227,916 hours in their lifetime… Dreaming about the life they...Timothy Sykes | SponsoredThe biggest threat isn’t ChinaWhile the headlines focus on AI models and chip speed, Elon Musk is investing in the material side of the stor...True Market Insiders | SponsoredBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeoGenomics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeoGenomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.